[{"innerBlocks":[],"name":"core\/freeform","postId":125915,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"Cancer specialists have long been the standard-bearers of precision medicine. Oncology was one of the first clinical areas to recognize the role genetic variations play in disease risk and causation. Subsequent progress has brought us to our current state, where oncologic therapies are targeted based on the tumor\u2019s genetic profile, rather than on the site where the disease presented itself.

Consider these realities:

BRCA 1 (associated with breast cancer) was discovered in 1994\u2014a full 25 years ago\u2014and BRCA 2 was identified just a year later<\/a>.<\/li>
Since then, it has been discovered that more than 50 cancer syndromes are affected by mutations in specific genes<\/a>.<\/li>
In 2017, pembrolizumab became the first tumor-agnostic drug approved by the FDA. Since then, several more have entered the market, including nivolumab and larotrectinib. The trend towards targeted molecular therapy is expected only to accelerate<\/a>.<\/li><\/ul>
Somatic results are not enough<\/b>
The results of somatic testing, which reveals genetic markers of the tumor tissue, has added great value to cancer treatment. Oncologists use these insights to more precisely diagnose a patient\u2019s disease and devise a care plan tailored to the unique molecular profile of the cancer. While incredibly important in the treatment of a specific incidence of cancer, somatic information does not provide information about the patient\u2019s \u201cnative\u201d genetic profile; a tumor\u2019s characteristics are unique unto itself. Therefore, somatic data provides limited information about the overall patient and other factors that might affect their care and wellbeing now and into the future.

As standard bearers, oncologists must look beyond somatic information, seeking and using a broader range of genomic data including germline and pharmacogenomic information to deliver the most effective care possible.

Leveraging pedigree and germline data<\/b>
Four specific areas come to mind, when we consider how oncology can maximize the value of genomics beyond the somatic view \u2013 which will lead to better outcomes and quality of life for patients.

Pedigree documentation to identify risk for prevention and earlier intervention.<\/b> Not long ago, I saw a young female patient who mentioned several family members had been diagnosed with breast cancer and ovarian cancer. We discussed benefits of genetic screening as well as other aggressive prophylactic options. While contemplating, she underwent mammography that unfortunately revealed Stage III cancer.

This was a sad and unnecessary outcome. Electronic health records should be capable of capturing critical family history enabling providers to spot areas of risk and concern \u2013 but, unfortunately, they do not. Instead, we need to leverage precision medicine tools designed to map a detailed patient pedigree so all providers, from PCPs to specialists, can assess heritable risk early, implementing in-time preventative and diagnostic measures.

The value extends beyond the patient him or herself, as well. Complete and detailed pedigree information can be shared with family members (and their providers) so they, too, can easily review familial patterns and more effectively identify genetic risk sooner.

The impact pharmacogenomic (PGx) information could have on the medications the oncologist prescribes.<\/b> Of course, somatic data can help the oncologist decide on the best treatment. Perhaps the patient\u2019s tumor exhibits markers like those examined in the TAILORx study4 for breast cancer \u2013 which means she does not need chemotherapy following surgery but would benefit equally well with hormone therapy (typically Tamoxifen). If the oncologist also had access to full PGx information, however, he would discover variants in the patient profile indicating she may not metabolize Tamoxifen well. With this information in hand, he can prescribe a different medication (such as an aromatase inhibitor) to manage her condition long term \u2013 and with greater success \u2013 instead.

PGx test results can reveal which nausea and pain drugs the patient metabolizes best, as well. This enables the oncologist to order the medications that will provide greatest relief with fewest side effects \u2013 the first time around, without time-consuming and frustrating trial and error.

Germline insights into co-morbidities and concurrent therapies.<\/b> When an oncologist refers only to somatic data, he or she sees a thin representation of the patient\u2019s overall situation. But it stands to reason that other diseases and treatments could impact the oncology care plan \u2013 and vice versa (cancer care could impact other clinicians\u2019 decisions and therapies). Access to full germline data, as well as treatment plans, means the oncologist can make more informed decisions about the best way forward. For example\u2026

Perhaps the cancer patient is also being treated for depression. The oncologist could refer to PGx information to guard against potential drug-drug-gene interactions between the antidepressant the patient takes and the aromatase inhibitor being used to support the patient\u2019s long-term, cancer-free survival.

Perhaps a breast cancer patient has also been diagnosed with rheumatoid arthritis. What are the implications of concomitant methotrexate therapy?

Future decisions about cancer care.<\/b> The goal of oncology treatment is partial or complete remission wherever possible. Nevertheless, it is not uncommon for the disease to recur or for a patient to develop a different type of cancer. Oncologists can better prepare for, and respond to, these occurrences when they have access to the patient\u2019s full germline data. (The somatic information they relied upon during the first course of treatment is no longer relevant.)

It is important to keep in mind that germline data is static. It rarely changes over time, which means a patient needs to undergo genomic testing only once. However, two other factors impacting health care are highly dynamic: 1] the patient\u2019s phenotype (observable characteristics and new symptoms) and 2] the body of knowledge around disease and treatment.

Oncologists who have ordered full germline testing and\/or have access to these results are able to re-interrogate the data as the patient\u2019s phenotype changes and science discovers more about genetic influence and targeted molecular therapies (provided their precision medicine software incorporates up-to-date knowledgebases). This means the oncologist can more quickly identify what the patient\u2019s emerging symptoms mean and what the most current therapeutic options are.

Precision medicine is undoubtedly becoming the new standard of care. Oncology forged healthcare\u2019s path into genomics and is poised to show the industry how to derive even greater benefit by leveraging insights from the full genome and by demanding tools that make the information actionable \u2013 both in today\u2019s environment and as tomorrow\u2019s scientific discoveries make their way into clinical practice.","saveContent":"Cancer specialists have long been the standard-bearers of precision medicine. Oncology was one of the first clinical areas to recognize the role genetic variations play in disease risk and causation. Subsequent progress has brought us to our current state, where oncologic therapies are targeted based on the tumor\u2019s genetic profile, rather than on the site where the disease presented itself.

Consider these realities:BRCA 1 (associated with breast cancer) was discovered in 1994\u2014a full 25 years ago\u2014and BRCA 2 was identified just a year later<\/a>.<\/li>
Since then, it has been discovered that more than 50 cancer syndromes are affected by mutations in specific genes<\/a>.<\/li>
In 2017, pembrolizumab became the first tumor-agnostic drug approved by the FDA. Since then, several more have entered the market, including nivolumab and larotrectinib. The trend towards targeted molecular therapy is expected only to accelerate<\/a>.<\/li><\/ul>
Somatic results are not enough<\/b>
The results of somatic testing, which reveals genetic markers of the tumor tissue, has added great value to cancer treatment. Oncologists use these insights to more precisely diagnose a patient\u2019s disease and devise a care plan tailored to the unique molecular profile of the cancer. While incredibly important in the treatment of a specific incidence of cancer, somatic information does not provide information about the patient\u2019s \u201cnative\u201d genetic profile; a tumor\u2019s characteristics are unique unto itself. Therefore, somatic data provides limited information about the overall patient and other factors that might affect their care and wellbeing now and into the future.

As standard bearers, oncologists must look beyond somatic information, seeking and using a broader range of genomic data including germline and pharmacogenomic information to deliver the most effective care possible.

Leveraging pedigree and germline data<\/b>
Four specific areas come to mind, when we consider how oncology can maximize the value of genomics beyond the somatic view \u2013 which will lead to better outcomes and quality of life for patients.

Pedigree documentation to identify risk for prevention and earlier intervention.<\/b> Not long ago, I saw a young female patient who mentioned several family members had been diagnosed with breast cancer and ovarian cancer. We discussed benefits of genetic screening as well as other aggressive prophylactic options. While contemplating, she underwent mammography that unfortunately revealed Stage III cancer.

This was a sad and unnecessary outcome. Electronic health records should be capable of capturing critical family history enabling providers to spot areas of risk and concern \u2013 but, unfortunately, they do not. Instead, we need to leverage precision medicine tools designed to map a detailed patient pedigree so all providers, from PCPs to specialists, can assess heritable risk early, implementing in-time preventative and diagnostic measures.

The value extends beyond the patient him or herself, as well. Complete and detailed pedigree information can be shared with family members (and their providers) so they, too, can easily review familial patterns and more effectively identify genetic risk sooner.

The impact pharmacogenomic (PGx) information could have on the medications the oncologist prescribes.<\/b> Of course, somatic data can help the oncologist decide on the best treatment. Perhaps the patient\u2019s tumor exhibits markers like those examined in the TAILORx study4 for breast cancer \u2013 which means she does not need chemotherapy following surgery but would benefit equally well with hormone therapy (typically Tamoxifen). If the oncologist also had access to full PGx information, however, he would discover variants in the patient profile indicating she may not metabolize Tamoxifen well. With this information in hand, he can prescribe a different medication (such as an aromatase inhibitor) to manage her condition long term \u2013 and with greater success \u2013 instead.

PGx test results can reveal which nausea and pain drugs the patient metabolizes best, as well. This enables the oncologist to order the medications that will provide greatest relief with fewest side effects \u2013 the first time around, without time-consuming and frustrating trial and error.

Germline insights into co-morbidities and concurrent therapies.<\/b> When an oncologist refers only to somatic data, he or she sees a thin representation of the patient\u2019s overall situation. But it stands to reason that other diseases and treatments could impact the oncology care plan \u2013 and vice versa (cancer care could impact other clinicians\u2019 decisions and therapies). Access to full germline data, as well as treatment plans, means the oncologist can make more informed decisions about the best way forward. For example\u2026

Perhaps the cancer patient is also being treated for depression. The oncologist could refer to PGx information to guard against potential drug-drug-gene interactions between the antidepressant the patient takes and the aromatase inhibitor being used to support the patient\u2019s long-term, cancer-free survival.

Perhaps a breast cancer patient has also been diagnosed with rheumatoid arthritis. What are the implications of concomitant methotrexate therapy?

Future decisions about cancer care.<\/b> The goal of oncology treatment is partial or complete remission wherever possible. Nevertheless, it is not uncommon for the disease to recur or for a patient to develop a different type of cancer. Oncologists can better prepare for, and respond to, these occurrences when they have access to the patient\u2019s full germline data. (The somatic information they relied upon during the first course of treatment is no longer relevant.)

It is important to keep in mind that germline data is static. It rarely changes over time, which means a patient needs to undergo genomic testing only once. However, two other factors impacting health care are highly dynamic: 1] the patient\u2019s phenotype (observable characteristics and new symptoms) and 2] the body of knowledge around disease and treatment.

Oncologists who have ordered full germline testing and\/or have access to these results are able to re-interrogate the data as the patient\u2019s phenotype changes and science discovers more about genetic influence and targeted molecular therapies (provided their precision medicine software incorporates up-to-date knowledgebases). This means the oncologist can more quickly identify what the patient\u2019s emerging symptoms mean and what the most current therapeutic options are.

Precision medicine is undoubtedly becoming the new standard of care. Oncology forged healthcare\u2019s path into genomics and is poised to show the industry how to derive even greater benefit by leveraging insights from the full genome and by demanding tools that make the information actionable \u2013 both in today\u2019s environment and as tomorrow\u2019s scientific discoveries make their way into clinical practice.","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

How precision medicine and genomics aid in cancer care

More for you